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Abstract
Perinatal drug abuse is becoming a profound issue facing the health and wellbeing of
neonates. The community serviced by the project site, which lies within the boundaries of
an Indian Reservation, suffers from perinatal drug abuse at a higher rate than state and
federal averages. The purpose of this project was to provide the project site with a policy
to consistently screen for perinatal drug abuse. Lave’s theory of situational learning and
the Sanford Way model for quality improvement framed this project. To guide policy
development, data were compiled through a systematic review of current literature,
national and state guidelines, state law, local tribal government, and community
stakeholders. Data included: (a) studies completed in the past 10 years specifically
targeting drug abuse in child-bearing aged women, with intentional exclusion of tobacco
and alcohol studies; (b) prevalence of illicit drug abuse in child bearing aged women at a
local, state, and national levels; and (c) local, state, and national guidelines, as well as
state law, for perinatal drug abuse intervention and screening. In addition, interviews and
meetings with local stakeholders were completed and their feedback was incorporated
into the development of the perinatal drug abuse screening and intervention policy. To
evaluate policy effectiveness, it is proposed that perinatal drug screens ordered at the
project site be monitored for six months prior to and after implementation of the new
policy. The desired outcome will be that providers consistently intervene with perinatal
drug abuse in a non-biased fashion. This quality improvement project will create a
positive social change by allowing non-biased intervention with perinatal drug abuse
using evidence-based practice and by promoting nursing-driven policy development.
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Section 1: Nature of the Project
Section 1
Introduction
It was not until the early 1970’s that teratogens such as alcohol were identified as
causing adverse infant outcomes, and it was not until 1990 that the Alcohol Beverage
Labeling Act of 1988 went into effect. This was the first intervention by the Surgeon
General focusing on substance abuse of pregnant women (Grant, 2009). According to the
literature, little has changed since the discovery of this public health concern. There are
more deaths, illnesses, and disabilities from substance abuse than from any other
preventable health condition (Healthy People, 2010). Perinatal drug abuse has become a
recognized health disparity of epidemiologic proportions (ASTHO, 2014). Infants
exposed to drugs during pregnancy can be diagnosed with neonatal abstinence syndrome
(NAS), requiring extensive medical treatment at birth and beyond. In the US, NAS rates
increased from 1.2 per 1,000 infants to 3.9 per 1,000 infants in 2009 alone (ASTHO,
2014). There has been a 33% increase in non-medical, opioid pain reliever use among
pregnant women in the past decade (ASTHO, 2014). Early treatment and intervention is
the key to successful outcomes for infants affected by substance abuse. Many studies
show that substance using women, particularly cocaine or opiate users, are significantly
less likely to obtain prenatal care (Schempf, 2009) and that substance abuse during the
preconception period predicts substance use during the prenatal period (Floyd, 2008).
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Background
Perinatal drug abuse is a growing problem for all communities in the United
States. The healthcare facility for this project is a critical access emergency department,
hospital, and rural health clinic located in northern Minnesota. The county in which the
facility lies is within the borders of an Indian Reservation. The project facility does not
currently have a policy on perinatal drug testing or perinatal drug use intervention. The
purpose of this project is to develop a policy to guide health care providers to test for and
intervene in perinatal drug abuse.
Facilities such as the project facility may be the only contact mothers have with
health care during their pre-conception, perinatal, and postnatal care states. It is very
important for health care providers to recognize the symptoms of drug abuse in women of
child bearing age and to have a policy for testing and intervention
Problem Statement
The state of Minnesota has been consistently ranked one of the lowest infant
mortality states in the US (MDH, 2013). However, Minnesota’s American Indian
children have a twofold greater incidence, compared to any other ethnic group of infant
mortality in their first year of life (MDH, project site, 2013). The county where the
project site is located has the highest rates of teen pregnancy, sexually transmitted
diseases, and drug and alcohol abuse among child bearing-aged women and the lowest
number of primary care providers per capita in the state (MDH, 2013). According to the
State Substance Use Report (2014), the students and adults in the county where the
project site resides are “considerably more likely to use tobacco, alcohol, illicit drugs and
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marijuana” (more than double the state average in all areas) than any other resident in the
state (SUMN, 2014).
Purpose Statement
According to Association of State and Territorial Health Officials (ASTHO)
(2014), “taking a public health approach to routine screening for unhealthy substance use
in women at every healthcare visit can help increase the opportunities for primary
prevention” (p. 2). The purpose of this project is to develop a healthcare facility policy to
guide health care providers to test for and intervene in perinatal drug abuse.
Project Goals and Objectives
The goal for this project is to develop a policy for the project site that will enable
providers (Nurse Practitioners and Physicians) to objectively screen child-bearing aged
women for drug abuse, by providing hospital and emergency department caregivers the
policy support needed to test for, and intervene with, positive drug screens.
Currently, the project site does not have a policy that will guide providers in
perinatal drug screening. This makes providers vulnerable to the assumption of bias when
testing or intervening with perinatal drug abuse. Globally, this project will remove those
assumptions of bias and give providers the support needed to properly intervene in
perinatal drug abuse. Specific objectives for this project will be to develop a perinatal
drug abuse policy based on National Guidelines established by the American Academy of
Pediatrics, American Academy of Obstetrics, Registered Nurses Association of Ontario,
evidence (Cochrane reviews), state law, and local tribal government recommendations.
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After graduation, future plans will be for project site leadership to implement the
policy system-wide for all health care providers to follow, as well as develop a formal
education program for all healthcare providers that will expand their understanding of
perinatal drug abuse. This quality improvement project will have future goals to lead this
facility towards a program that will (a) identify health care providers’ current philosophy
on drug screening, (b) educate providers on the need for a policy to manage perinatal
drug abuse, (c) develop a policy for all emergency room and hospital providers to test for
perinatal drug abuse, and (d) establish a protocol for intervention when perinatal drug
abuse is diagnosed.
Theoretical Framework
Lave and Wenger developed a learning theory based on the assumption that
individuals learn according to the situation they are in and that there is a direct correlation
between learning and the situation the individual is in (Wenger, 1991). Laves Theory of
Situation Learning will be used as a theoretical framework when developing the project.
Laves theory implies that learning requires that the context of information be presented as
authentic and that it take place in settings and situations in which it would normally occur
(Knowledgebase, 2011). Laves theory is a practice theory and requires interaction
between all parties. (Knowledgebase, 2011).
Significance to Practice
Nurses are not typically strong in policy development and are historically known
to “shy away from leadership opportunities” (Mason, 2013, p. xxvii). Doctorate-prepared
nurses are called upon to lead their field in policy development and social change.
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Development of system policy, by nurses, will positively impact the future of nursing
mentorship within the nursing profession. Nursing is working diligently to develop a
culture of nursing mentorship within this profession that goes above and beyond the
individual and organizational level (Montavlo, 2015).
Evidence-Based Significance
The need to screen, test, and intervene with perinatal drug abuse is a lake filled
with murky water for practicing providers. Prescription drug abuse in the US alone has
reached epidemic proportions. McHugh (2015) stated “The rapid escalation of this
problem initially far outpaced clinical research on its nature and on interventions to
prevent and treat prescription drug use disorders” (p. 2). Providers are unclear of their
role in perinatal drug abuse and are in need of evidence-based policies that will guide
their assessment and intervention of this epidemic problem.
Implications for Social Change
The Child Abuse and Prevention and Treatment Act (CAPTA) was amended in
2003 to include the “Keeping Children and Families Safe Act” which allows funding for
states contingent on their establishment of procedures that keep safe infants born to illicit
drug abuse (Farst, 2011). This act provides protection to providers to screen for drug
abuse in pregnancy, but leaves the decision of who and when to test at the discretion of
the provider. Farst (2011) stated objective protocols are needed to avoid bias towards
newborns of minority or poverty backgrounds. To avoid the suspicion of provider bias,
every healthcare facility should develop a policy to address perinatal drug abuse testing
(Farst, 2011).
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Definition of Terms
The principal terms used throughout this QI project are defined next.
Perinatal: According to the World Health Organization (WHO), perinatal period
begins at 22 weeks gestation and ends at 7 days post-partum (WHO, 2013).
Illicit drug abuse: For this purpose of this project, illicit drug abuse is limited to
marijuana, opiate (prescription as well as non-prescription), methamphetamine, and other
illegal chemicals for mood alteration.
Critical access hospitals (CAH): Are rural hospitals that meet defined criteria
outlined by the federal government and are reimbursed by cost-based measures (Center,
2011).
Screening: For the purpose of this project refers to the process of determining
drug abuse in women in the perinatal period. Screening involves assessment of findings,
lab testing, and history and physical exam.
Neonatal Abstinence Syndrome (NAS): Is a syndrome of symptoms noted in
infants during the perinatal period that is caused from a sudden cessation of exposure to
illicit drugs. NAS is diagnosed by using the Finnegan Scoring System (Kocherlakota,
2014).
Limitations and Assumptions
Limitations to development of a perinatal drug abuse policy at the project site are
related to provider acceptance of policy and professional collaboration. Team approach is
a strategy that will help facilitate physicians, nurses, and all other stakeholders engaged
in perinatal drug abuse prevention, to work collaboratively to improve patient outcomes
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(White, 2012). Assumptions for this quality improvement project are that the policy is
designed specifically for the need of one facility, and that the goals, mission and vision of
this project align specifically with this one facility. Limitations also include the fact that
the DNP student researcher of this project is employed at the facility this program is
being designed for. This will potentially create personal bias due to previous experience
working with perinatal drug abuse in this facility. Although this is a limitation, it can
also be a benefit in that the DNP student is familiar with providers, facility processes, and
the population served.
Summary
The project site is currently without a policy that can be used by emergency room
and hospital providers when intervening with perinatal drug abuse. There is a need for a
site-specific policy that will guide providers to intervene with perinatal drug abuse.
Without a policy for intervention in place, providers are subject to accusations of bias. A
perinatal drug abuse policy will provide an avenue for early recognition and intervention
with drug abuse in all child bearing aged women.
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Section 2: Review of Literature and Theoretical and Conceptual Framework
Literature Review
Specific Literature
Perinatal drug abuse and infants born with NAS have increased at an alarming
rate in the US (Patrick, 2012). The project site does not currently have a policy that
guides health care providers to screen, test, or intervene with perinatal drug use. Without
a facility policy in place, it is left up to the discretion of the provider to determine the
need for testing, relying on personal judgment (Birchfield, 1994). The project site is a
critical access hospital and ED in an underserved, high risk county that was ranked the
“least healthy county” in its home state in 2014 (Robert Wood Johnson, 2014). Testing
and screening for perinatal drug abuse is critical to intervention (ASTHO, 2014). The
purpose of this project is to develop a policy that will guide health care providers at the
project site to screen and test for perinatal drug abuse and intervene when needed.
Literature Search and Strategy
Ten databases were used for the purpose of searching the literature. Google
Scholar, Mayo Clinic, Sanford Health, Walden University Library database search of
CINAHL, PubMed, MEDLINE, Nursing and Allied Health Score, and the Cochran
Database of Systemic Reviews were searched. Key search terms used were


testing for drug abuse in pregnancy



health policy drug abuse



pregnancy drug abuse



pregnancy testing policy
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perinatal testing policy



neonatal abstinence syndrome



illicit drug abuse pregnancy



pregnancy outcomes



drug abuse pregnancy risk factors



Minnesota statues perinatal drug exposure



perinatal drug abuse

The scope of the literature review for this paper was broad. Early literature on
NAS and policy needs were found in the late 70s- early 90s. The majority of the literature
used was collected from 2000- 2014.
It is noted that a Tribal Chairwoman announced at the 14th annual Communities
Collaborative Brain Development Conference (held August 12-14, 2014) that 80% of all
Native American babies born at two local birthing centers were positive for drugs. This is
important to the findings for this paper as the project site lies entirely within the borders
of and Indian Reservation, and is the only hospital and ED on this reservation. During the
search for information it was noted that statistics and specific data regarding tribal
members are protected, often not shared with non-tribal affiliates, or not collected at all.
For the needs of this project, the evidence, literature and databases searched, were done
so at a national, state, and county level and applied to this community. National, state and
county data were reviewed for the purpose of this proposal, has been aggregated and
extrapolated to fit this needs of this specific site.
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General Literature
Neonatal abstinence syndrome is a diagnosis given to infants born with specific
symptoms of drug withdrawal at birth (Finnegan, 1974). The most commonly utilized
tool for diagnosis of NAS is the Finnegan scoring system (Kushel, 2007). The Finnegan
scoring system is a system that allows a health care provider to identify and score specific
withdrawal symptoms. A Finnegan score above 7 typically indicates the need for
treatment of NAS (Kushel, 2007). In the past decade there has been a significant rise in
the number of US births diagnosed with NAS. Diagnosed cases have rose from 1.2 per
1,000 US births to 3.39 per 1,000 births. (ASTHO, 2014). More than 13,000 infants were
born with drug withdrawal symptoms in 2009, which means approximately one infant is
born with NAS every hour in the US (ASTHO, 2014). This is likely not a true
representation of the number of infants born with NAS, as maternal drug abuse is underreported, there is commonly no prenatal care, infants are born outside of a health care
setting, and Finnegan scoring is subjective to user assessment (Houdak, 2012). In 2013
The Department of Health & Human Services, Substance Abuse and Mental Health
Services (SAMHSA), released the results from their 2012 National Survey on drug abuse
and reported that among pregnant women, aged 15 to 44 years, 4.0% used illicit drugs in
the past month, 11.8% reported current alcohol use, 2.9% reported binge drinking, and
16.5% of pregnant women used tobacco in the last month.2 In the United States, nearly
90% of drug-abusing women are of reproductive age. Substances most commonly abused
during pregnancy include cocaine, amphetamines, opioids, marijuana, ethanol, tobacco,
caffeine, and toluene-based solvents.
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Great controversy surrounds perinatal drug screening. The need for policy to
guide testing has increased as the number of infants born with exposure has increased. In
an early study on the need for policies to test for drug abuse in pregnant women,
Birchfield (1994) stated, “the process by which pregnant women and infants are selected
for illicit drug testing has caused concern because it may lead to bias and
overrepresentation of certain populations in the drug-using groups.” (p. 211). The
Association of State and Territorial Health Officials (ASTHO) suggested that “taking a
public health approach to routine screening for unhealthy substance use in women at
every healthcare visit can help increase the opportunities for primary prevention” and
recognizes the following lifetime frames as key time frames for interventions
“preconception, during pregnancy, at birth, postpartum or neonatal/infancy period, and
childhood and beyond” (ASTHO, 2014, p.3).
Lindsay (2013) recommended “parturients identified as drug users” receive a
comprehensive management approach involving both “high risk obstetrics, and
comprehensive counseling” (p. 140). Recognition of this profound social problem has
healthcare leaders pushing for universal screening of all child bearing aged women, and
certainly for all pregnant women. ASTHO (2014) stated:
States can support the American Congress of Obstetricians and Gynecologists’
(ACOG) recommendation for universal substance use screening in early
pregnancy in a variety of ways. State agencies, quality improvement efforts, and
perinatal collaborative can advance prenatal screenings as the expected standard
of care for obstetric providers. State health agencies can ensure that Medicaid
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reimburses for substance abuse screening, support provider education and
training, and streamline entry points for substance abuse treatment. Need page
number
The literature regarding perinatal substance abuse has proved consistent results.
There is a national, as well as, global need for interventions surrounding perinatal
substance abuse. In addition, there is a need for further screening and policies for drug
screening and testing, which are specific to women, and pregnant women. For the
purpose of this study, emphasis will be placed on those studies that only address
substance abuse in pregnancy and reproductive aged women.
Perinatal Drug Abuse Studies
The following review will examine: (a) five quantitative research studies
conducted by Azadi and Dildy (2008), Pinto et al. (2010), Schempf and Strobino, (2009),
Smith et al. (2009), and Vucinovic et al. (2008); (b) two qualitative studies by Nueshotz
and Fitzpatrick (2008) and Walkup et al. (2009); and, (c) two meta-analyses conducted
by Greenfield et al. (2010) and Howell et al. (1998).
Purposes
One quantitative and one qualitative article focused on identifying the prevalence
of substance abuse, as well as, factors that interfere with screening and intervention of
substance abuse problems (Azadi & Dildy, 2008; Neushotz & Fitzpatrick, 2008). Two
quantitative studies focused on the contribution of substance abuse to negative outcomes
in pregnancy (Pinto et al., 2010; Vucinovic et al.. 2008). Two quantitative studies focused
on the correlation of maternal substance abuse and little to no prenatal or mental health

13
care (Schempf et al., 2009; Smith et al., 2009). The purpose of one qualitative study was
to evaluate the efficacy of a home-visit intervention program among young, reservation
based American Indian mothers and their increased parenting knowledge, including a
reduction in perinatal substance abuse (Walkup, 2009).
Designs
Due to the nature of perinatal substance abuse and the fear of stigmatization and
discrimination, many pregnant women keep the use of illicit drugs from their providers.
Because of this, it is not surprising that the large majority of controlled studies are
retrospective cohort studies (Azadi & Dildy, 2008; Neushotz & Fitzpatrick, 2008; Pinto
et a.., 2010; Schempf & Strobiono, 2009; Smith et al., 2009; and Vucinovic, 2008). All
six of the retrospective studies were longitudinal with durations ranging from four
months to ten years. One research study used a longitudinal, double blind trial of a home
based intervention for young reservation based American Indian mothers (Walkup,
2009).
Samples
Sampling refers to the way study participants are selected, and a sample refers to
the segment of a population that is selected to participate in the study (Rubin, 2008).
Many of the quantitative studies had large sampling sizes. For example, Vucinovic et al.
(2008) looked at statistical data from 43,181 deliveries at Split University Hospital in
Croatia, this was the only study noted using data from outside the US. This sampling
method resulted in a study sample of 85 mothers that continued in the study. The samples
in the quantitative studies varied greatly from 85 in the study by Vucinovic (2008) to 812
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in the study by Schempf (2009). Of the randomized controlled trials, one had a sample
size of 167 (Walkup et al., 2009) and one study did not clearly identify the sampling
process or the sample size (Neushotz & Fitzpatrick, 2008).
Methods and Measures
Methods and measures varied between the studies. Three of the quantitative
articles specifically noted only using data analysis (Pinto et al., 2010; Schempf &
Strobino, 2009; Vucinovic et al., 2008). The data gathered and analyzed by Pinto et al.,
(2010) came from patients’ records and specifically focused on demographic details,
smoking, and past and present history of drug use, current antenatal problems, and selfreported or clinically discovered substance use. Schempf and Stobino (2009) focused on
data pertaining to low income, one or no prenatal visits, and positive drug screens.
Vucinovic et al., (2008) analyzed data on all pregnancies complicated by illicit drug use
over a 10 year period at Split University Hospital.
Azadi and Dildy (2008) screened pregnant women who delivered at University
Hospital in New Orleans in the first four months of 2005. On admission for labor, women
were screened by urine toxicology testing for substance use. Demographic, labor, and
outcome data were obtained from the records of those patients who tested positive. Those
patients were also interviewed at the hospital during their labor admission. Those with
positive urine toxicology screens and negative delivery outcomes were included in the
sample. In the study by Smith et al. (2009), pregnant and postpartum women who tested
positive underwent a diagnostic evaluation, were provided at least one mental health
referral, and were encouraged to seek treatment for substance abuse, as well as,
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depressive disorders. Follow up evaluations were done on these women at one month,
three months, and six months. Logistic regression was used to estimate the relationship
between clinical and psychosocial factors and self-reported mental health service use.
The qualitative studies had two different methods and measures. Neushotz and
Fitzpatrick (2008) conducted interviews with the clinic staff from a major metropolitan
academic hospital in New York City. The staff included Physicians, Resident Physicians,
one Social Worker, and seven Registered Nurses. The initial interview was conducted
with the Director of Nurses and the Medical Chief. Notes, reflections, and recordings of
the meetings between the clinicians were analyzed extracting information on adherence
to current practice guidelines regarding substance abuse screening. Walkup et al. (2009)
conducted a study of expectant American Indian mothers aged 12-22 years randomized
into one of two home visit intervention groups. The intervention began during pregnancy
and continued to six months postpartum. They focused on prenatal and newborn care
with specific emphasis on substance abuse, among other things. Mothers and children
were evaluated at baseline, two months, six months, and twelve months post-partum.
Approaches to Analysis
Data were collected and recorded in a number of different data bases. Stata was
used by Pinto et al. (2010), Microsoft Office Access was used by Azadi & Dildy (2008),
and Vucinovic et al., (2008) reported using SPSS 10. Five studies reported using the chisquare test to determine bivariate associations between factors, namely the variables and
controls. Four of the five studies using the chi-square test were quantitative (Azadi &
Didly 2008; Pinto et al., 2010; Schempf & Strobino, 2009; Vucinovic et al., 2008) and
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one study was qualitative (Walkup et al., 2009). Of these studies, the p value benchmark
for establishing statistical significant was <0.05. The Mann-Whitney rank sum was also
used for normally distributed and skewed data in the Azadi and Dildy (2008) and Pinto et
al. (2010) studies, and for statistical data analysis of quantitative data in the Vucinovic et
al., (2008) study. The Smith et al. (2009) study used multivariate analysis to categorize
variables between pregnant and post-partum women.
Findings
Three of the qualitative studies focused on negative pregnancy outcomes related
to substance abuse. The three studies by Azadi and Dildy (2008), Pino et al. (2010), and
Vicinovic et al., (2008) resulted in similar findings, and noted there were a significant
number of births affected by substance abuse. Pino et al. (2010) stated that (19)% of
pregnant women screened positive for drugs. According to Pinto and colleagues (2010)
adverse fetal outcomes were most likely to occur when illicit substances were used
during pregnancy and manifested most commonly as low birth weight, and placental
abruption.
Five of the studies focused on treatment and screening. Three of the studies were
quantitative (Pinto et al., 2010; Schempf & Strobino, 2009; Smith et al., 2009) and two
were qualitative (Neushotz & Fitzpatrick, 2008; Walkup et al., 2009). The results of three
studies were similar (Neushotz & Fitzpatrick,2008;, Schempf & Stobine,2009;Smith et
al.2009); all found there to be limited screening, as well as, limited prenatal care for
substance abusing mothers. Of those mothers who were screened and tested positive for
drug use, there were neither interventions nor treatment programs available to pregnant or
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postpartum women. Walkup et al. (2009) found evidence to support an in-home
intervention for pregnant, American Indian women. This study followed the success rates
of an in home perinatal support group that provided evidence of decrease in the number
of positive perinatal drug screens in mothers that completed the program.
Two literature reviews were also used for the purpose of strengthening an
understanding of the available data. Greenfield et al. (2006) examined the literature
containing characteristics associated with treatment outcomes in women with substance
use disorders and found that women with substance use disorders are less likely over their
lifetime to enter treatment compared to their male counterparts. Howell et al. (1998)
conducted a literature review to determine the information on perinatal drug abuse
available in 1998. Howell also wanted to gain insight to the level of progress made in
combating the social injustice called perinatal substance abuse.
In 1998, Howell et al. reported:
The prevalence of perinatal illicit drug use is known to be about 5% of all
pregnant women nationwide, with higher rates for selected subgroups. Local
studies have shown much higher rates. Substance abuse is associated with
poverty, with the substance abuse of significant others, and with family violence.
Perinatal substance abusers experience poorer birth outcomes (p.196).
Reports of both literature reviews agreed with the data found in the research
studies. There were a significant number of perinatal substance abusers and perinatal
substance abuse had a negative impact on the health of the mother, as well as, the child.
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The greatest weakness found in all studies is unavoidable. It is not ethical to
knowingly study women who are actively taking illicit drugs while pregnant. Therefore,
all of the studies required collection of retrospective data. The studies also relied heavily
on self-reported data. Many of the authors recognized this as an inherent weakness of the
data. Neushotz and Fitzpatrick (2008) did not clearly list a sample size. They reported
the total patient population and the numbers of patients that each primary care provider
treated annually. The authors also listed the numbers of those patients who were male and
female, as well as, the numbers of females who had used illicit drugs. The reader
assumed this was the control group, but it was not listed as such. There were potential
biases in both of the studies (Pinto et al., 2010; Vucinovic et al., 2008) that focused on
the effects of substance abuse on pregnancy. Those biases included body mass index not
recorded in either study, which could affect birth weight and hypertensive disorders. Data
on HIV and Hepatitis was not collected in the Pinto et al. (2010) study, but was in the
Vucinovic et al. (2008) study. This is an important omission since HIV and Hepatitis can
both affect birth outcomes also.
Results
Results of six studies reported the incidence of perinatal substance abuse, effects
on pregnancy and neonatal outcomes, as well as, the success of screening and treatment
(Azadi & Dildy, 2008; Neushotz & Fitzpatrick, 2008; Pinto et al., 2010; Schempf and
Strobino, 2009; Smith et al., 2009; Vucinovic et al., 2008). Unanimously, they reported
that perinatal substance abuse resulted in negative pregnancy outcomes such as preterm
delivery, low birth weight, placental abruption, neonatal hemorrhagic stroke, and an
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increased incidence of infection in the neonate. Walkup et al. (2009) found fewer reports
of perceived stress or substance abuse in the mothers who received early pregnancy
perinatal drug abuse
Characteristics of individual studies included in this paper are presented in
Table A-1 Summary of Study Characteristics (See Appendix B).
National Guidelines
American College of Obstetricians and Gynecologists (2014) states “screening for
substance abuse is a part of complete obstetric care and should be done in partnership
with the pregnant woman. They also state “all women should be routinely asked about
their use of alcohol and drugs, including prescription opioids and other medications used
for nonmedical reasons” (p.2). The American Academy of Pediatrics (2013) states “the
primary care pediatrician’s role in addressing prenatal substance use should include
prevention, identification of exposure, recognition of medical issues for the exposed
newborn infant, and regular follow-up to monitor any long-term effects” (p.a1009).The
American Nurses Association (ANA), (2011) states “registered nurses working in the
perinatal field to seek out appropriate rehabilitation and therapy treatment for women
abusing substances (illicit or prescribed drugs, and/or alcohol) and to identify and offer
appropriate therapy to infants exposed to these substances” (p.1). National certifying
bodies, and national guidelines suggest that screening and intervention is necessary in
appropriate treatment of perinatal drug abuse.
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State Law
The states of Minnesota has specific statues that pertain to perinatal drug testing.
Statue 626.556, Reporting of maltreatment of minors reads:
626.5561 REPORTING OF PRENATAL EXPOSURE TO CONTROLLED
SUBSTANCES.§ Subdivision 1.Reports required.
(a) Except as provided in paragraph (b), a person mandated to report under
section 626.556, subdivision 3, shall immediately report to the local welfare
agency if the person knows or has reason to believe that a woman is pregnant and
has used a controlled substance for a nonmedical purpose during the pregnancy,
including, but not limited to, tetrahydrocannabinol, or has consumed alcoholic
beverages during the pregnancy in any way that is habitual or excessive.
(b) A health care professional or a social service professional who is mandated to
report under section 626.556, subdivision 3, is exempt from reporting under
paragraph (a) a woman's use or consumption of tetrahydrocannabinol or alcoholic
beverages during pregnancy if the professional is providing the woman with
prenatal care or other healthcare services.

Theoretical Framework
Background
As the literature suggests, perinatal substance abuse can be seen in many settings
in health-care. The policy designed from this DNP project will be universal to any health
care provider, and will be able to be used in both the emergency department, and the
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hospital at the project facility. The clinicians guided by this policy will need be educated
in their specific settings. The project leader has used Laves Theory of Situational
Learning in previous projects where collaboration and interaction were key components
to learning. This project will require information presented to be specific to the project
setting and will be best presented in the environment of the project site.
Lave’s Theory of Situational Learning
Lave’s Situational Learning Theory will be used as the theoretical framework to
guide this project including the development of a perinatal drug abuse policy for the
project site. Lave’s Theory of Situational Learning states that learning is situated, that is,
as it normally occurs. Learning is embedded within our culture and activity and it is
usually unintentional rather than deliberate (Knowledgebase, 2011). Situational Learning
Theory is a practice theory that requires that learning take place in settings or situations
that are normal to that environment. Practice theories are used in the actual delivery of
patient care to clients. They are also used to carry out nursing interventions, as well as
educating patients and staff, and communicating with patients and staff. Social
interaction and collaboration between all parties are essential components of Lave’s
theory. Situated learning requires that knowledge be presented in its authentic context, or
in settings and situations that would normally involve that setting (Knowledgebase,
2011).
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Evidence Based Practice Model: The Sanford Way
Conceptual Model
The Sanford Way is a work improvement model that allows users to see
improvement in a different way. This model focuses on initiating change by identifying
opportunities for improvement, including the subjects of the change in planning the
interventions, and substantiating change by monitoring and evaluating outcomes (Rodak,
2012). Sanford Way Model of Change has three key components including people,
process, and performance.
Each component of the model has identified principles. The people component
incorporates building people and their capacity for work, learn through relentless
reflection and continuous improvement, make technology fit people, and support people
by creating efficient and reliable processes. The process component includes eliminating
waste, error-proofing systems, designing work where the safest process is the easiest,
liberating human creativity by establishing standard work, and creating connected
process flows to improve performance. The performance component aligns with Sanford
Rational Standards, sustains change for reliable outcomes, and utilizes evidence-based
practice (Rodak, 2012). This model will be used to develop a perinatal drug abuse policy
for the project site. (See Figure 1)
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Figure 1. The Sanford Way model of quality improvement is an improvement
methodology that allows us to identify improvement options that support the needs of all
involved (Rodak, 2012).
Summary
Perinatal drug abuse directly causes poor, often devastating, birth outcomes
(ASTHO, 2014). All health care providers will need the best tools possible to combat this
critical health problem. There is a need at the project facility for a policy that guides
providers to non-biased, screening, assessment, recognition, and intervention of perinatal
drug abuse. The project site does not currently have a policy in place for perinatal drug
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screening or intervention. Leadership organizations in the field of perinatal care suggest
facilities adopt a policy when managing perinatal drug abuse, use, or suspected use. The
development of a policy will support health care providers in using non-biased care to
address this profound issue while promoting nursing theory guided practice, as well as
nursing leadership in policy development, and clinical scholarship.
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Section 3: Approach
Introduction
The purpose of this project was to develop a policy for the project site that will
enable providers (Nurse Practitioners and Physicians) to objectively screen child-bearing
aged women for drug abuse, by providing hospital and emergency department caregivers
the policy support needed to test for, and intervene with, positive drug screens
This policy is needed to guide providers at the project to approach and intervene
with this problem in a non-biased manor. This section will outline the process for
curriculum development, implementation and evaluation of this quality improvement
project. The following outlined the steps were taken to develop this project.
1. Identify key stakeholders
2. Assemble the team
3. Identify barriers and limitations to the development of this policy
4. Set Goals, objectives for perinatal drug abuse policy formation and guide the
team to assess relevant evidence.
5. Seek Institutional Review Board approval at study site and Walden.
6. Develop the project site’s perinatal drug policy based on the Sanford Way
model, national standards and recommendations, and special interest
recommendations.
7. Develop a plan for implementation of policy.
8. Develop an evaluation plan.
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Project Team
Team members were chosen based on their knowledge, and by their investment in
the project site, as well as their interest in quality improvement within the system.
According to Kelly (2013), it is critical to identify and understand the systems structure
and the structures influence on behavior. To have success in implementing lasting change
efforts, it is important to press oneself to “go below the waterline”, meaning that if we
target interventions to change what we do, rather than what causes the system to work the
way it does, change will be temporary and we will not have “gone below the waterline”
(Kelly, 2013, p. 36-38). The goal of this project will be to go below the waterline, thus
implementing long standing change in the management of perinatal substance abuse.
Team members for this quality improvement project will include:
1. Team leader: The DNP student author of this project who will function as
facilitator.
a. Team leader will specifically develop policies and procedures and
accompanying documents for perinatal drug abuse intervention. The
team leader will develop the policy and procedure based on State and
National guidelines as well as recommendation of local special interest
groups.
2. Administration representative/ CEO of Project Site
a. Evaluation and implementation will be monitored/managed by the
CEO or administrative representatives such as the CNO or QI officers.
3. Chief Nursing Operator (CNO) at Project Site
a. Evaluation and implementation will be monitored/managed by CNO or
representative, administrative representatives, and the QI officer.
4. Provider representative.
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a. Implementation and continued participation will be the responsibility
of participating providers.
5. Quality Improvement (QI) Officer of Nursing.
a. Evaluation and implementation will be monitored/managed by QI
officer, the CNO representative, and the CEO Representative.
Development of the project site’s Perinatal Drug Policy
Ethical Considerations
The researcher submitted all paperwork required to obtain approval from Walden
Universities Internal Review Board (IRB), as well as the project site facilities
management officers. Special consideration will be made to avoid any race-specific
interventions in this policy.
Developing the Policy
Evidence leads to the recognition that there must be a policy in place for health
care providers to address perinatal drug abuse. The lack of such a policy leaves providers
vulnerable to the assumption of provider bias when perinatal drug abuse is recognized
and interventions are ordered or implemented. Development of this policy was specific to
the project site, and the needs of the community they serve. The policy is based on
National and State guidelines, recommendations from both the American Academy of
Pediatrics and American Academy of Obstetrics, American Nurses Association, as well
as local special interest groups. Stakeholders and team members were interviewed for
input and opinion during the development phase of the policy. The policy will be
reviewed for content and validity by the CEO as well as the medical committee. The
policy will go through an approval process as all policies do at the project facility.
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Planning Implementation of the Policy
Project site stakeholders and leadership personnel were included in planning the
implementation of the policy. Evidence for the need of a policy for perinatal drug abuse
was presented to stakeholders and leadership. The policy was developed by the project
leader and is specific to the project site. The project leader used current state and local
laws, as well as evidenced based on guidelines set forth by ACOG, the American
Academy of Pediatrics, and the ASTHO. Using the Sanford Way model for
implementation, the project leader identified opportunities for improvement, included the
subjects of the change in planning the interventions, and plans to sustain change by
monitoring and evaluating outcomes (Rodak, 2012).
Develop Evaluation Plan
Evaluation of this perinatal drug abuse policy began in the planning phase of this
project. This evaluation plan was discussed with the stakeholders in the early
development stages. Following are the suggested steps to be taken during this evaluation,
the steps are varying and may be conducted simultaneously or cyclic (Hodges, 2011. p.
210-211).
1. Engage stakeholders
2. Describe the program.
3. Conceptualize the evaluation.
4. Design the evaluation
5. Chose and test the instruments and procedures.
6. Collect evaluation data.

29
7. Analyze and report data.
8. Make changes to the program based on the data.
9. Evaluate again.
Evaluation will focus on the number of child-bearing aged women that are
screened for pregnancy and perinatal drug abuse beginning at least six months prior to
implementation of the policy, as well as six months after the implementation of the
policy.
Evaluation of the program is vital when planning and processing any project.
Evaluation must help show program success, improvement, and whether the program is
meeting its goals and objectives (Hodges, 2011). Evaluation of this policy will take place
at a later time, and will not be part of this project.
Summary
Perinatal drug abuse is a profound problem faced in healthcare today. Providers at
the project site do not have a policy in place to guide assessment, diagnosis and
intervention of perinatal drug abuse. With the lack of policy, providers are vulnerable to
the assumption of provider bias when intervening with perinatal drug abuse. Through
nursing leadership, collaboration, and nursing policy development providers will be given
the tools needed to assess, diagnose and intervene with perinatal drug abuse.
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Section 4: Findings, Discussions and Implications

To recap, the was to develop a policy for the project site that will enable providers
(Nurse Practitioners and Physicians) to objectively screen child-bearing aged women for
drug abuse, by providing hospital and emergency department caregivers the policy
support needed to test for, and intervene with, positive drug screens
This project is relevant to nursing practice by alleviating the assumption of health
care provider bias, as well as placing nurse leaders into position of policy development
through promotion of nursing leadership. Development of system policy, by nurses, will
positively impact the future of nursing mentorship within the nursing profession.
The goal of this project was to impact social change by identifying and
intervening with perinatal substance abuse, in system supported manor. This intervention
will lead to better total wellbeing of communities, families and individuals suffering from
perinatal drug abuse.
The objectives of this project were to develop a policy for a critical access
hospital, in a high risk area, who is currently operating without a policy, and who is
currently leaving perinatal drug abuse intervention to individual decision, thus implying
bias. This section will discuss the project and its implications, strengths and limitations,
and the analysis of the DNP students self.

Discussion of Project Product
This facility policy was developed to intervene with perinatal drug abuse in a nonbiased manor, thus having a positive impact on perinatal drug abuse and improving
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outcomes for communities, providers, and patients. The policy was developed taking
recommendations from national guidelines set forth by accredited bodies as well as from
stakeholders at the facility, and special interest stakeholders from the community.
Discussion of Findings
Program Development
After receiving IRB approval from Walden University, the project leader in
motion a series of meetings with project site stakeholders. Meetings included face-to-face
visits, telephone conference, emails conversations, and group meetings. Meetings were
attended by DNP student (project leader) and site stakeholders (including the CEO, CNO,
QI Nurse, and special interest representatives from the community). During these
meetings, a perinatal drug abuse policy was discussed; input from these stakeholders,
available literature and national guidelines, guided the development of this policy.
The policy was written in the format used by this facility for policy development.
National guidelines recommend that every health care facility have a policy that protects
providers from the assumption of bias when screening for perinatal drug abuse. The data
collected suggested there are specific adverse outcomes that can be seen with perinatal
drug abuse such as vascular accidents, placental abruption, preterm labor, perinatal infant
mortality, and hypertension in pregnancy to name a few. These specific adverse outcomes
were included in the policy. There is significant evidence that child-bearing aged women
are at risk for perinatal drug abuse. Kuczkowski (2007) reported ‘in the United States
nearly 90% of drug-abusing women are of reproductive age. Polysubstance abuse is very
common” (p. 578).
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The community in which this project site lies is affected by perinatal drug abuse
at a higher rate than state average, it is estimated that this community has a 60% greater
chance of perinatal drug abuse than other Minnesota communities (Enger, 2014). This
project site is the only hospital or emergency department located for more than 60 miles
of this service community. This facility does not perform prenatal care or labor and
delivery care; they transfer patients to regional delivering centers. In 2010, nearly 3
percent of mothers delivering at the two closest regional delivering facilities tested
positive for drugs the day of their child's birth. In 2013, that number more than doubled
to more than 6.5 percent (Enger, 2014). This community was recognized to have greater
than average need for perinatal drug abuse intervention and a grant was given to one of
the regional delivery centers for a 1.6 million dollar perinatal drug intervention program
(Enger, 2014). Stakeholders in this community have recognized the need for immediate
intervention in perinatal drug abuse at the project site as well.
Currently, providers at the project site are left to determine the need to screen for
pregnancy or perinatal drug abuse at their own personal discretion. There is no policy in
place to guide that determination. This leaves providers vulnerable to the assumption of
bias when determining the need for pregnancy or drug screens. The development of this
policy will alleviate the assumption of bias and provide the community with appropriate,
evidence-based, and consistent interventions for the profound problem of perinatal drug
abuse.
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The developed policy will require that any female of child bearing age (14-55),
presenting to the ED for; (a) drug overdose (intentional or un-intentional), (b) those
needing treatment with a schedule I-IV medication have a pregnancy screen. Perinatal
patients that presents to the ED with the following conditions must have a drug screen
(which could include a quantitative screen if the provider feels this is appropriate): (a)
those in labor or have delivered prior to admittance, (b) placental abruption, (c) evidence
of unexplained or poor weight gain in pregnancy, (d) MI or CVA in a child bearing aged
woman, or HTN in pregnancy, (e) admitting to, or evidence of, poor or no prenatal care,
(f) admitting to illicit drug abuse, (g) fetal demise, (h) at the request of county or tribal
social services, (i) if health care provider exam, or history intake dictates.
Implementation Plan
The policy was developed specifically for the project site. The project team
recognized the need for a policy and accepted the presentation of the project and agrees
with the need for a policy. Senior leadership at the project site identified the need for a
policy as a priority, and agreed that the groundwork has been laid for policy
implementation.
Although the developed policy was submitted to the project site, senior leadership
has voiced their understanding that project evaluation is needed and they will decide
when or if the project site will ultimately implement the policy. An evidence based
evaluation plan was proposed to the team of stakeholders, along with the project. The
evaluation plan reflects that which was laid out in the project proposal. During project
planning meetings, it was often voiced that there is much work to do in the future of
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perinatal drug abuse at the project site. Access to follow up, post hospital care, and
treatment were recognized as the greatest future concerns for the project site. The policy
can be referenced in Appendix A.
Evaluation Plan
Evaluation of the project was also presented to the project team. Planning for
evaluation began at the onset of the project. The evaluation plan presented suggests that
drug screens, as well as pregnancy screens, are tracked for six months prior to and after
implementation of the policy. If at any time during the evaluation leadership identifies
concerns for the policy, changes could be made to the policy that will promote perinatal
drug use interventions. It is suggested that tracking of drug and pregnancy screens be
completed by nursing staff via the electronic medical record.
Specifically, it is suggested that for a period of 6 months before and after
implementation of the project, a log of every female of child bearing age, that presents to
the ED for (a) drug overdose (intentional or un-intentional), (b) those needing treatment
with a schedule I-IV medications and have a pregnancy screen. It is also suggested that
the log record all perinatal patients that present to the ED with the following conditions
which require a drug screen (a) those in labor or have delivered prior to admittance, (b)
placental abruption, (c) evidence of unexplained or poor weight gain in pregnancy, (d)
MI or CVA in a child bearing aged woman, or HTN in pregnancy, (e) admit to or
evidence of poor or no prenatal care, (f) admitting to illicit drug abuse, or (g) at the
request of county or tribal social services.
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It is suggested this log be kept for six months prior and six months after
implementation of the policy.
Implications
Practice
This DNP project has used evidence to identify the need for policy development.
This project allowed this student to lead a team of stakeholders and to develop a policy
that will lead to practice change at the project facility. Policy development by DNP
prepared nurses is needed to elevate the professional status of nursing. Bartels (2005)
stated “the AACN has adopted a new position that recognizes the DNP degree as the
highest level of preparation for clinical practice” (p 233). DNP nurse leaders are
encouraged to become active in leadership, and policy development. As a DNP student,
and through the DNP curriculum, this student learned to recognize practice problems, and
can utilize the skills needed to translate evidence into practice problem solutions.
This project allowed the student to develop a policy that will positively impact the
current perinatal drug abuse problem facing practitioners at the project site; it will also
eliminate the suspect of provider bias. This is a health problem that the student feels
passionate about intervening with. As this student has lived and worked in this
community her entire life, she has personally seen the devastating effects of perinatal
drug abuse. The student has also experienced the unfortunate consequences of drug
screening without a policy, and being accused of biased behavior when doing so.
Screening and testing for perinatal drug abuse can be difficult. Prasad (2014)
stated, “Despite the adverse outcomes associated with exposure to tobacco, alcohol, and

36
illicit drugs, only approximately 20% of ob/gyns effectively screen patients for illicit
drug use” (n.p.). Prasad (2014) identified provider embarrassment, fear of upsetting
patients, and uncertainty of where to turn with positive results as barriers to screening.
Policy Development
Creating a perinatal drug screening policy is supported by the literature as
evidenced by recommendations from professional organizations that lead health care
policy. After a thorough review of the evidence, and referring to national guidelines, as
well as meeting with both project site and community stakeholders, a policy for perinatal
drug abuse screening was developed for the project site. This project will positively
impact provider practice by intervening with the escalating health problem of perinatal
drug abuse while eliminating provider bias.
Future Research
Research supports a policy for perinatal drug screening. Future research
anticipated to stem from this project will include perinatal drug abuse treatment, and long
term substance abuse care. Project site stakeholders have identified the need for future
research into long term intervention, and management of perinatal drug abuse, as a
priority problem for this project site.
Social Change
The nursing profession claims is founded on evidence-based practice. From the
times of Florence Nightingale nurses have used evidence-based practice to guide clinical
decision making (White, 2012). The rural health setting is a perfect setting for nurses
(who are not known to be policy makers), to use evidence-based practice and take a
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leadership role in policy development. Rural health nurse practitioners are required to
practice at the top of their scope using autonomous, evidence-based practice. It is
important for rural health NPs to use their experience and knowledge to guide policy
development, and change the culture of policy making to be nursing driven. This
evidence based practice policy allows nursing to take a leadership role in policy
development.
Strengths and Limitations
There are many strengths to this DNP practice project. An evidenced based
practice policy will allow providers to screen for, and intervene with, perinatal drug
abuse in a non-biased manor. It will give providers comfort knowing they are intervening
with this significant, complex health care problem, but also are protected from the
pressures of bias. Currently, providers at the project site have no policy in place and are
simply intervening based on their own personal knowledge and preference. This project
is strengthened yet by the fact that it was developed based on up-to-date research,
national and special interest recommendations, and state law.
Limitations of the project include that is developed for a particular site, and is less
generalizable for other rural health facilities. The project will delivered to site leadership
and will be implemented at their discretion, if at all.
Analysis of Self
In pursuit of my doctoral degree, I have felt significant personal and professional
growth. I have worked as a rural health NP for the past five years. I have worked without
a policy for perinatal drug abuse that entire time. Unfortunately, I have been involved in
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situations where I myself have been accused of personal bias when intervening with
perinatal drug abuse without a policy. This DNP project has given me the opportunity to
impact this truly devastating community health problem, while pushing myself into a
nurse leadership role. I recognize that nurses are not predominantly policy makers. I felt a
personal need to focus my project on policy development, and was very happy that my
project can impact perinatal drug abuse, and support nurses and physicians alike by
eliminating the suspicions of bias.
Summary
Perinatal drug abuse is rapidly becoming one of the most profound issues facing
the health and wellbeing of neonates. Provider recognition of, and intervention for,
perinatal drug abuse is often left to provider discretion and bias. Without a policy in place
to guide health care providers, the assumption of bias can be detrimental to intervention.
This policy project will support health care providers at the project site, and encourage
them to intervene with perinatal drug abuse and every possible encounter.
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Section 5:
Project Summary
Introduction
Perinatal drug abuse is rapidly becoming one of the most profound issues facing
the health and wellbeing of neonates. Provider recognition of, and intervention for,
perinatal drug abuse is often left to provider discretion and bias. Policy to recognize,
assess, and intervene in perinatal drug abuse is necessary for all providers, and will
alleviate any potential provider bias, as well as provide guidance and direction for
intervention.
Project Goal
The primary project goal is to develop a policy for the project site that will enable
providers (Nurse Practitioners and Physicians) to objectively screen child bearing aged
women for drug abuse, by providing hospital and emergency department caregivers the
policy support needed to test for, and intervene with, positive drug screens. Specific
objectives for this project will be to develop a perinatal drug abuse policy based on
National Guidelines established by the American Academy of Pediatrics, American
Academy of Obstetrics, RNAO, evidence (Cochrane reviews), state law, and local tribal
government recommendations.
Approach
This quality improvement project engaged a team of stakeholders which included
both facility and community representatives, using evidence based practice, developed a
site specific perinatal drug abuse policy.
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Results
An evidence based practice policy was developed that will support providers
screening, testing, and intervening with perinatal drug abuse, protecting provider from
assumption of bias.
Implication for practice
Nurses are not typically strong in policy development and are historically known
to “shy away from leadership opportunities” (Mason, 2013, p. xxvii). Doctorate-prepared
nurses are called upon to lead their field in policy development and social change.
Development of system policy, by nurses, will positively impact the future of nursing
mentorship within the nursing profession. Nursing is working diligently to develop a
culture of nursing mentorship within this profession that goes above and beyond the
individual and organizational level (Montavlo, 2015).
Background, Purpose and Nature of the Project
Background
Perinatal drug abuse is a growing problem for all communities in the United
States. The project facility is a critical access emergency department, hospital and rural
health clinic located in northern Minnesota. The county in which the facility lies is within
the borders of an Indian Reservation, The project facility does not currently have a policy
on perinatal drug testing or perinatal drug use intervention. The current status quo is to
leave all perinatal drug screening to the determination of the provider, leaving the
provider vulnerable to accusation of bias.
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Purpose
According to Association of State and Territorial Health Officials (ASTHO)
(2014), “taking a public health approach to routine screening for unhealthy substance use
in women at every healthcare visit can help increase the opportunities for primary
prevention” (p. 2). The purpose of this project was to develop a policy for the project site
that will enable providers (Nurse Practitioners and Physicians) to objectively screen
child-bearing aged women for drug abuse, by providing hospital and emergency
department caregivers the policy support needed to test for, and intervene with, positive
drug screens.
Nature of the Project
Evidence leads to the recognition that there must be a policy in place for health
care providers to address perinatal drug abuse. The lack of such a policy leaves providers
vulnerable to the assumption of provider bias when perinatal drug abuse is recognized
and interventions are ordered or implemented. Development of this policy was specific to
the project site, and the needs of the community they serve. The policy is based on
National and State guidelines, recommendations from both the American Academy of
Pediatrics and American Academy of Obstetrics, American Nurses Association, as well
as local special interest groups, and state and local law. Stakeholders and team members
were interviewed for input and opinion during the development phase of the policy.
Project Design and Setting
This DNP Project was designed to be implemented by providers at the project
site. The project began by meeting with project site management and determining the
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greater need at the project. Perinatal drug abuse intervention was identified as a great
need at the project site. Extensive review of the evidence revealed that intervention must
be supported by policy to prevent suspicion of provider bias. After receiving approval by
the project site and Walden University’s Institutional Review board, a team of project site
leadership, community stakeholders and the project leader were called upon for advice
throughout policy development.
Interpretation of Results
A policy for perinatal drug abuse screening and intervention is imperative to
protect providers from assumption of bias. Lindsay (2013) recommended “parturients
identified as drug users” receive a comprehensive management approach involving both
“high risk obstetrics, and comprehensive counseling” (p. 140). Recognition of this
profound social problem has healthcare leaders pushing for universal screening of all
child bearing aged women, and certainly for all pregnant women. ASTHO (2014) stated:
States can support the American Congress of Obstetricians and Gynecologists’
(ACOG) recommendation for universal substance use screening in early
pregnancy in a variety of ways. State agencies, quality improvement efforts, and
perinatal collaborative can advance prenatal screenings as the expected standard
of care for obstetric providers. State health agencies can ensure that Medicaid
reimburses for substance abuse screening, support provider education and
training, and streamline entry points for substance abuse treatment (p.6).
The literature regarding perinatal substance abuse has proved consistent results.
There is a national, as well as, global need for interventions surrounding perinatal
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substance abuse. In addition, there is a need for further screening and policies for drug
screening and testing, which are specific to women, and pregnant women.
American College of Obstetricians and Gynecologists (2014) states “screening for
substance abuse is a part of complete obstetric care and should be done in partnership
with the pregnant woman. They also state “all women should be routinely asked about
their use of alcohol and drugs, including prescription opioids and other medications used
for nonmedical reasons” (p. 2). The American Academy of Pediatrics (2013) stated “the
primary care pediatrician’s role in addressing prenatal substance use should include
prevention, identification of exposure, recognition of medical issues for the exposed
newborn infant, and regular follow-up to monitor any long-term effects” (p.a1009).The
American Nurses Association (ANA), (2011) stated “registered nurses working in the
perinatal field to seek out appropriate rehabilitation and therapy treatment for women
abusing substances (illicit or prescribed drugs, and/or alcohol) and to identify and offer
appropriate therapy to infants exposed to these substances” (p. 1). National certifying
bodies, and national guidelines suggest that screening and intervention is necessary in
appropriate treatment of perinatal drug abuse.
Implication for Practice
This DNP project has used evidence to identify the need for policy development.
This project allowed me to lead a team of stakeholders, and to develop a policy that will
lead to practice change at the project facility. Policy development by DNP prepared
nurses is needed to elevate the professional status of nursing. Bartels (2005) stated “the
AACN has adopted a new position that recognizes the DNP degree as the highest level of
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preparation for clinical practice” (p. 233). DNP nurse leaders are encouraged to become
active in leadership, and policy development. As a DNP student, and through the DNP
curriculum, I have learned to recognize practice problems, and can utilize the skills
needed to translate evidence into practice problem solutions.
Conclusion
This DNP project resulted in the development of an evidence based practice
policy that will support providers at the project site, minimizing assumption of bias and
will meet the needs of the community by positively intervening with perinatal drug abuse.
Perinatal drug abuse is a significant community health problem that will require
intervention at every opportunity. Without this evidence based project, the facility and its
surrounding communities are at risk of missing the opportunity to intervene with
perinatal drug abuse, and providers are at risk for the assumption of bias. Upon final
approval, and meeting all requirements of this DNP degree, the policy will be submitted
to the facility site (along with a 12 month evaluation plan) with the hopes that the project
site will follow the evidence, support their providers and community, and implement this
perinatal drug abuse policy. The facility policy can be referenced in Appendix A

45

References
Abuse, S. (2013). Results from the 2012 National Survey on Drug Use and Health:
Summary of National Findings (No. NSDUH Series H-46, HHS Publication
No.(SMA) 13–4795). Rockville, MD: Substance Abuse and Mental Health
Services Administration.
Albright, B., Rayburn, W., (2009) Substance abuse among reproductive age women.
Obstetrical and Gynecological Clinics of North America (36). p.891-906.
American Academy of Pediatrics (AAP), (2013). Prenatal substance abuse: Short- and
long-term effects on the exposed fetus. Retrieved from:
http://pediatrics.aappublications.org/content/131/3/e1009.full.pdf+html
American College of Obstetricians and Gynecologists (ACOG), (2014). Committee
Opinion. Opioid abuse, dependence, and addiction in pregnancy. Retrieved from
http://www.acog.org/-/media/Committee-Opinions/Committee-on-Health-Carefor-Underserved-Women/co524.pdf?dmc=1&ts=20150807T1212256145
American Nurses Association (ANA), (2011). Position Statement. Non-punitive alcohol
and drug treatment for pregnant and breast-feeding women and their exposed
children. Retrieved from
http://www.nursingworld.org/mainmenucategories/ethicsstandards/ethicsposition-statements/non-punitive-alcohol-and-drug-treatment-for-pregnant-andbreast-feeding-women-and-the-exposed-childr.pdf

46
Association of State and Territorial Health Officials (ASTHO), (2014). Neonatal
abstinence syndrome: How states can help advance the knowledge base for
primary prevention and best practices of care. Retrieved from:
http://www.astho.org/Prevention/NAS-Neonatal-Abstinence-Report/
ASQ (2011). Plan do check act (PDCA) cycle. Retrieved from http://asq.org/learn-aboutquality/project-planning-tools/overview/pdca-cycle.html
Azadi, A., Dildy, G., (2008). Universal screening for substance abuse at the time of
parturition. American Journal of Obstetrics & Gynecology,e30-e32.
Bartels, J. E. (2005). Educating nurses for the 21st century. Nursing & health
sciences, 7(4), 221-225.
Bentley, S., Melville, J., Berry, B., & Katon., ? (2007) Implementing a clinical and
research registry in obstetrics: overcoming the barriers. Hospital Psychiatry,
p.192-198.
Birchfield, M., Scully, J., & Handler, A. (1994). Perinatal screening for illicit drugs:
policies in hospitals in a large metropolitan area. Journal of perinatology: Official
Journal of the California Perinatal Association 15(3), p.208-214.
Bond, S., (2008). Successful substance abuse treatment program for pregnant women
delivers new model of care. Journal of Midwifery & Womens Health (28) p.567568.
Center, R. A. (2011). Critical access hospitals. Retrieved from
http://www.aha.org/advocacy-issues/cah/index.shtml

47
Cohen, D. A., & Reporting, A. (2015). Substance Abuse and Mental Health Services
Administration 6.
D'Apolito, K., (2008). Neonatal opiate withdrawal: Pharmacological management.
Neonatal Nurse Practitioner Program, Vanderbilt University, Nashville:
Newborn and Infant Nursing Reviews. p. 62-69.
Department of Health (2008). National survey on drug use. Alcohol use among pregnant
women and recent mothers: 2002 to 2007. Department of Health and Human
Services, Triangle Park: Department of Health and Human Services.
Enger, J. (2014), MPRNEWS. Drug education program targets at-risk mothers in
northern Minnesota. Retrieved from
http://www.mprnews.org/story/2014/11/12/northern-minnesota-drug-education

Farst, K. J., Valentine, J. L., & Hall, R. (2011). Drug testing for newborn exposure to
illicit substances in pregnancy: pitfalls and pearls. International journal of
pediatrics, 2011.
Finnegan, L. P., Connaughton Jr, J. F., Kron, R. E., & Emich, J. P. (1974). Neonatal
abstinence syndrome: assessment and management. Addictive diseases, 2(1-2),
p.141-158.
Floyd, R., Jack, B., Cefalo, R., Atrash, H., Mahoney, J., Herron, A., Husten, C., & Sokol,
R., (2008). The Clinical content of preconception care: Alcohol, tobacco and
illicit drug exposures. American Journal of Obstetrics & Gynecology, p.S333S339.

48
Grant, T., Huggins, J., Sampson, P., Ernst, C., Barr, H., Streissguth, A., (2009). Alcohol
use before and during pregnancy in western washington, 1989-2004: Implications
for the prevention of fetal alcohol spectrum disorders. Amercian Journal of
Obstetrics & Gynecology. p.278e1-278e8.
Greenfeild, S., Brooks, A., Gordon, S., Green, C., Kropp, F., McHugh, K., …& Miele, G.,
(2007). Substance abuse treatment entry, retention, and outcome in women: A
review of the literature. Drug and Alcohol Dependence (86). p.1-21.
Hathaway, J., Zimmer, B., Willis, G., Silverman, J., (2008). Perceived changes in health
and saftey following participation in health care-based domestic violence
program. Journal of Midwifery & Womens Health (53). p.547-555.
Howell, E., Heiser, N., Harrington, M., (1998) A review of rescent findings on substance
abuse treatment for pregnant women. Journal of Substance Abuse Treatment
(16)3. p.195-219.
Hodges, B., Videto, D. (2011). Assessment and planning in health programs. Jones &
Bartlett Learning.
Husley, T., Prenatal drug use: The ethics of testing and incarcerating pregnant women.
Newborn and Infant Nursing Reviews 5, no. 2 (2005): 93-96.
Hudak, M. L., Tan, R. C., Frattarelli, D. A., Galinkin, J. L., Green, T. P., Neville, K. A.,
... & Watterberg, K. L., (2012). Neonatal drug withdrawal. Pediatrics. 129(2),
pp.e540-e560.
Kelly, D. (2013). Applying quality management in healthcare. A systems approach.
Chicago IL: Health Administration Press

49
Klima, C., Norr, K., Vonderheld, S., Handler, A., (2009). Introduction of centering
pregnancy in a public health clinic. Journal of Midwifery & Womens Health
(54)1. pp. 27-34.
Knowledgebase, Learning Theories. (2011). Situated Learning Theory (Lave). Retrieved
from: http://www.learning-theories.com/situated-learning-theory-lave.html
Kocherlakota, P. (2014). Neonatal Abstinence Syndrome. Pediatrics, (134)2, e547-e561.
Kovalesky, A., (2004).Women with substance abuse concerns. Nursing Clinics of North
America (39) pp. 205-217.
Kuschel, C. (2007). Managing drug withdrawal in the newborn infant. In Seminars in
Fetal and Neonatal Medicine. 12(2), pp. 127-133.
Kuczkowski, K. M. (2007). The effects of drug abuse on pregnancy. Current Opinion in
Obstetrics and Gynecology, 19(6), 578-585.
Lindsay, M. K., & Burnett, E. (2013). The use of narcotics and street drugs during
pregnancy. Clinical obstetrics and gynecology, 56(1), pp. 133-141.
Marcus, S., Heringhausen, J., (2009). Depression in childbearing women: When
depression complicates pregnancy. Primary Care Clinics of North America (36).
pp. 151-165.
Martin, S., Kilgallen, B., Dee, B., Dawson, S., Campbell, J., (1998). Women in a
prenatal/substance abuse treatment program: Links between domestic violence
and mental health. Maternal and Child Health (2)2. pp. 85-94.
Mason, D. J., Leavitt, J. K., & Chaffee, M. W. (Eds.). (2013). Policy and Politics in
Nursing and Healthcare-Revised Reprint. Elsevier Health Sciences.

50
McGuinness, P., Pollack, D., (2008). Parental methamphetamine abuse and children.
Journal of Pediatric Health Care. (22)2. pp. 152-158.
McHugh, R. K., Nielsen, S., & Weiss, R. D. (2015). Prescription drug abuse: from
epidemiology to public policy. Journal of substance abuse treatment, 48(1), 1-7.
Minnesota Department of Health, (2013). Infant Mortality in Minnesota. Retrieved from
http://www.mchb.hrsa.gov/infantmortalitysummit/mnimreportchicagosummit.pdf
Minnesota Revisor of Statues (2009). 626.5561: Reporting of prenatal exposure to
controlled substances. Retrieved from https:
www.revisor.mn.gov/statues/?id=626.5661.
Mittendorfer, E., Wasserman, D., (2008). Pregnancies in high psychosocial risk groups:
research findings and implications for early intervention. Psychiatric Clinics of
North America (31). pp. 205-212.
Montavlo, W., & Veenema, T. G. (2015). Mentorship in Developing Transformational
Leaders to Advance Health Policy: Creating a Culture of Health. Nurse Leader,
13(1), 65-69.
Neushotz, L., Fitzpatrick, J., (2008). Improving substance abuse screening and
intervention in a primary care clinic. Archives of Psychiatric Nursing. (22)2. pp.
78-86.
Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M.,
& Davis, M. M. (2012). Neonatal abstinence syndrome and associated health care
expenditures: United States, 2000-2009. JAMA, 307(18), 1934-1940.

51
Pinto, S., Walkinshaw, S., Siney, C., Kakkar, P., & Mousa, H., (2010). Substance abuse
during pregnancy: Effect on pregnancy outcomes. European Journal of Obstetrics
& Gynecology and Reproductive Biology, pp. 1-5.
M. Prasad, M., (2014). When opiate abuse complicates pregnancy. ObstetricsGynecology & Women’s Health. retrieved from
http://contemporaryobgyn.modernmedicine.com/contemporary
Ramirez-Cacho., (2007). Medical students' attitudes twoard pregnant women with
substanc use disorders. American Journal of Obstetrics & Gynecology. (86). pp.
86e1-86e5.
Rayburn, W., (2007). Materanl and fetal effects from substance abuse. Clinics in
Perinatology. pp. 559-571.
Robert Wood Johnson Foundation (2014). County health rankings and roadmap: Key
findings report. Retrieved from
http://www.countyhealthrankings.org/sites/default/files/2014%20County%20Heal
th%20Rankings%20Key%20Findings.pdf
Rodak, S., (2012). The Sanford way to quality: Developing and enterprise wide
improvement strategy. Retrieved from:
http://www.beckershospitalreview.com/quality/the-sanford-way-to-qualitydeploying-an-enterprise-wide-improvement-strategy.html
Rubin, A., (2008). Practitioners guide to using reaserch for evidence- based practice.
New Jersey: John Wiley & Sons. Schempf, A., Strobino, D., Drug use and limited

52
prenatal care: an examination of responsible barriers. Americal Journal of
Obstetrics and Gynecology, April 2009: 412e1-412e10.
Seng, J., Sperlich, M., Kane, L., (2008). Mental helath demographic, and risk behavior
profiles pf pregnant survivors of childhood and adult abuse. Journal of Midwifery
& Womens Health. pp. 511-520.
Smith, M., Shao, L., Howell, H., Wang, H., Poschman, K., & Yonkers, K., (2009).
Success of mental health refferal among pregnant and postpartum women with
psychiatric distress. General Hospital Psychiatry. (31). pp. 155-162.
Strathearn, L., Mayes, L., (2010). Cocaine addiction in mothers: Potential effects on
maternal care and infant development. The New York Academy of Sciences. pp.
172-183.
Substance Use in Minnesota (SUMN), (2014). Mahnomen County. Retrieved from
http://www.sumn.org/~/media/143/MAHNOMEN%20COUNTY%202014%20S
UMN%20Fact%20Sheet.pdf
Vucinovic, M., Roje, D., Vucinovic, Z., Capkun, V., Bucat, M., & Banovic, I., (2008).
Maternal and neonatal effects of substance abuse during pregnancy: Our ten year
experience." Yonsei Medical Journal. (49)5. pp. 705-713.
Wenger, E. and Lave, J., 1991. Situated Learning: Legitimate Peripheral Participation
(Learning in Doing: Social, Cognitive and Computational Perspectives) by.
Cambridge University Press, Cambridge, UK.

53
Walkup, J., Barlow, A., Mullany, B., Pan, W., Goklish, N., Hastings, R.,… & Reid, R.,
(2009). Randomized controlled trail of a paraprofessional in-home intervention
for your reservation-based American Indian mothers. Journal of American
Academy of Child and Adolescent Psychiatry. (48)6. pp. 591-601.
White, K., Dudley-Brown, S., (2012). Translation of evidence into nursing and
healthcare practice. Springer Publishing Company.
World Health Organization, (2014). Maternal and perinatal health. Retrieved from
http://www.who.int/maternal_child_adolescent/topics/maternal/maternal_perinata
l/en/

54
Appendix A

Title: Perinatal Drug Abuse Intervention: Policy for Drug Screening
Created: 10/2015
PURPOSE: To provide policy and procedure for perinatal drug abuse screening.
Definitions:
Childbearing aged women: for this policy that will include women ages 14-55.
Poor or no prenatal care: defined as less than two prenatal visit in their first trimester, less
than one per month in their second trimester, and less than two visits per month in their
third trimester.
Policy:
Urine drug screen will be ordered by the facility provider based on criteria stated in this
policy, as well if the medical or psychosocial assessment made by the provider indicates
the necessity.
If substance abuse is discovered, proper medical, social and mental health support will
be provided, and reporting will comply with Minnesota State Statues 626.556 and
626.5561, “Reporting of Maltreatment of Minors” and “Reporting of Perinatal Exposure
to Controlled Substances”.
Procedure:
1) Admitting nurse, and provider will screen any childbearing aged women for
perinatal drug abuse.
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2) On the occasion that any of the following factors are identified, a urine pregnancy
test, as well as urine toxicology screen, will be collected.
Drug overdose (intentional or un-intentional), (b) those needing
treatment with a schedule I-IV medication, (c) any identified, or
clinical suspicion of, illicit drug use in a child bearing aged woman.
3) Perinatal (or known pregnant) patients that presents to the ED with the following
condition(s) must have a drug screen (which could include a quantitative screen if
provider feel this is appropriate).
(a) Those in labor or have delivered prior to admittance, (b) placental
abruption, (c) evidence of unexplained or poor weight gain in
pregnancy, (d) MI, CVA or unexplained tachycardia in a child bearing
aged woman, or HTN in known pregnancy, (e) admittance to, or
evidence of, poor or no prenatal care, (f) admitting to illicit drug
abuse, or (g) fetal demise, or (h) at the request of county or tribal
social services.
4) Although informing the patient is preferred, the drug screen does not require
patient or parent permission.
5) The facility social worker will be notified of confirmed perinatal drug abuse, and
will notify the appropriate Human Services, Child Protection, or Indian Child
Welfare office. This report will be submitted, in writing, within 72 hours of the
visit.
Copyright Joeanna Larson FNP-C. This policy was created for the exclusive use by the project site
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Appendix B
Table 1: Summary of Study Characteristics
Authors and Year
Zadi, A., Didly, G.,
(2008)
Universal
screening for
substance abuse at
the time of
parturition

Bently et al.,
(2007)
Implementing a
clinical and
research registry in
obstetrics:
overcoming
barriers

Subjects,
Sample
Four hundred
sixty two
women that
delivered
during the first
four months of
2005 at a New
Orleans
Obstetrics
department.

Study Purpose

Study Type

To determine the
prevalence of
substance abuse in
an inner city
population at
delivery admission
by universal
toxicology
screening

A Retrospective
Cohort

All patients 15
years and older
that were
cognitively able
to complete the
survey that
were admitted
to the obstetric

To define the
obstacles and
solutions in
developing and
implementing a
prospective
obstetrics database
registry that

ObservationalLongitudinal,
Prospective Cohort
study

Instrument;
Analysis
Universal
toxicology
screening results,
compared to
demographic, labor
and outcome data.
The seven
substances tested
for were
amphetamines,
cocaine,
barbiturates,
opiates,
benzodiazepine,
and phencyclidines.

Findings

Questionnaire
given to all
obstetric patients in
one clinic over a
specific period of
time

A mental health
registry that
merges clinical
data and research
needs can be
successfully
integrated into the
obstetrical setting.

Nineteen percent
of the tested
population tested
positive for one of
7 substances at
admission for
delivery.
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Schmpf, A.,
Strobino, D.,
(2008)
Drug use and
limited prenatal
care: an
examination of
responsible barriers

clinic at
Harborview
medical clinic
during an
unspecified
time frame.
812 lowincome women
who delivered
at Johns
Hopkins
Hospital

collects
biopsychosocial
data on women
during pregnancy
and postpartum
To determine
sociodemographic,
psychosocial and
health belief
factors that
explain the
association
between maternal
drug use and little
or no prenatal
care.

Retrospective
Cohort study.

Analysis of
toxicology screens,
medical records,
and self-reported
drug use. Survey
given to those
mothers
determined to have
used drugs.

Adjustments for
sociodemographic
characteristics and
cocaine and opiate
use were
predictive of little
or no prenatal
care. The effects
of cocaine were
explained by
psychosocial
factors; external
locus of control,
fear of being
reported. Where
opiate use
remained strongly
related to little or
no care in fully
adjusted models.
Therefore,
different outreach
and education
strategies may be
necessary with
cocaine VS
opiates.
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Smith et al., (2009)
Success of mental
health referral
among pregnant
and postpartum
women with
psychiatric distress

Walkup et al.,
(2009)
Randomized
controlled trial of a
paraprofessional
delivered in home
intervention for
young reservation
based American
Indian mothers

initially 465
pregnant and
postpartum
women
receiving care
from publicly
funded
obstetric clinics
between April
1 and June 25th
2005.
Teenage, first
time,
unmarried,
mothers living
in reservation
communities,
with
interventions
beginning
during
pregnancy and
continuing until
12 months post
partum.

To measure the
rates of and
determined factors
associated with
mental health
services use
among 465
pregnant and
postpartum
women.

Prospective Cohort
study

Diagnostic
evaluation
screening tool.

Rates of mothers
accessing and
particularly
continuing in
mental health
treatment were
low.

To evaluate the
efficacy if a
paraprofessional
delivered home
visiting Family
Spirit intervention
among young,
reservation based
American Indian
mothers on
parenting
knowledge,
involvement and
maternal infant
outcomes with
emphasis on
parenting
knowledge, social
support, stress,
depression and
substance abuse.

Treatment,
Randomized
Double Blind study

25 “Family Spirit”
home visits were
performed with the
treatment group
and 23 breast
feeding/nutrition
education
interventions were
performed with the
active control
group. Evaluation
done at baseline, 2
moths post partum,
6 months post
partum and 12
months post
partum.
A computerized
collection of data
to ensure
randomization.

The study
supports the
efficacy of the
paraprofessional
delivered Family
Spirit home
intervention for
young American
Indian mothers on
maternal
knowledge and
infant behavior
outcomes.
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Curriculum Vitae
Joeanna Larson RN, FNP, MSN
16126 160th Ave NE
Thief River Falls MN, 56701
Cell: (218) 358-0558
Email: joeanna.larson@sanfordhealth.org

OBJECTIVE: Provided as an attachment to Capstone Project intended to meet the
requirements of graduation from Walden University, DNP Program.
QUALIFICATIONS: I am a certified Family Nurse practitioner with Sanford
Health Systems. I am a motivated, skilled, compassionate and determined. I have lived in
this community my entire life, and am vested in the health and wellness of this
community.
EDUCATION
1999-2001 Diploma in Nursing, LPN, Itasca Community College
2001-2002 Associate Degree, RN, Northland Community and Technical
College
2006-2008 Bachelor of Science Degree, BSN, Bemidji State University
2008-2011 Master Degree, MSN, University of North Dakota
2013-Current Enrolled at Walden University, DNP program expected
graduation date February, 2015
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EMPLOYMENT
2001-2002 LPN, Clearwater County Memorial Hospital- Bagley Minnesota
Clearwater County hospital is a rural county hospital that has approximately fifteen beds.
As an LPN at Clearwater Hospital my responsibilities included assessments, med pass,
ADLs, assisting in the Emergency Room, lab, and x-ray. Working in a rural hospital
helped to build the foundation of my nursing experience in such a way as to promote
critical thinking as the driving force of my care.
2002-2011 RN, North Country Regional Hospital – Bemidji Minnesota. I was
employed in Outpatient Surgery and Recovery Room. Responsibilities included the
assessments and admissions of surgical patients both inpatient and out. I work half of my
hours in admissions and half in recovery. Our Recovery Room is a critical care area
where as an RN I am responsible for the care of all surgical cases. Assessment and
patient advocacy are my most utilized skill.
I was employed on the Family Care Center at North Country. Family Care Center
consists of three separate areas; 1-Med/Surg. 2. Pediatrics and 3. Labor and Delivery,
Newborn Nursery and Post Partum. On family care I spent the first year working as a
staff RN on the Med-Surg. /Pediatrics floor. Following one year of experience I began
working primarily in Labor and Delivery. During the last three years of my employment
on Family Care worked as the fulltime Night Charge Nurse for the Family Care Center
which consisted of being the charge nurse for all three areas of the department. In 2007 I
transferred departments and began working in the OPS/PACU department. PACU is a
critical care department in which I served as a fulltime BSN.
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In 2008 I served as adjunct faculty at Northland Community and Technical
College. Summer session 2008 I taught Maternal Child Health and Adult Nursing II on
the Mahnomen Minnesota Campus. Fall 2008 I served as a structured tutor to the
Graduating RN students on the Thief River Falls Minnesota campus.
In 2010 I served as a GTA (Graduate Teaching Assistant) at the University of
North Dakota. I served as a Clinical Instructor for the Postpartum and Newborn
clinical rotation. As well as lead discussion group twice weekly. I was also responsible
for the correction and grading of the student care plans and portfolios.
2011-2015 I worked as an FNP for Sanford Health Systems, at the project site. I
am a skilled FNP working full time as family practice provider in the clinic and ED
setting. The project site is the primary hospital and ED caring for the residents of a large
Indian Reservation.
In August 2014 I taught at Bemidji States University as faculty for advanced
skills II and clinical II.
9/2015- Present: I transferred within Sanford system to Thief River Falls clinic
where I am working two days per week in Internal Medicine clinic and two days per
week in Urgent Care. I also cover the Emergency Department one weekend per month.
8/2015- Present I began teaching with Northland Community and Technical
College in the Associate RN program. I am teaching Clinical I and Clinical II currently.
OTHER QUALIFICATIONS
I currently hold ACLS, PALS and CALS certifications. I am certified to implant
Nexplanon and Merena birth control.
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2013- present I have been working in collaborative effort with White Earth
Chemical Dependency, White Earth Mental health, Mahnomen Social services, Indian
Child Welfare and the Department of Health to create a community based, collaborate
approach to substance abuse on the White Earth Reservation. This group has actively
taken a role in the recent opening of Odapinaan Giwiidookage Onijinaan, a residential, all
male, inpatient addiction/treatment facility among many other substance abuse programs
and interventions within our community. The goal of this collaborative effort is to open a
detox center, and inpatient female residential program as well.
I served as the President of the Board of Directors for Bagley Youth Hockey
association and have been on the board since 5/2004. In 2007 and 2008 I served as the
student representative to Bemidji State University, Department of Nursing’s Advisory
Board. I assisted Clearwater County Nursing Services in surveillance and implementation
of their county health survey, fall 2007.

